Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TYMP | P19971 | 9/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765886 | 1.00 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL21901418 | 0.95 | KDM4E (0.52) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL10533862 | 0.94 | KDM4E (0.41) | KDM4ETYMP | |
| SCHEMBL21901666 | 0.94 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL17911715 | 0.93 | KDM4E (0.40) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL7202323 | 0.92 | KDM4E (0.49) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL24115430 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL13255852 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL7999585 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL18510955 | 0.91 | KDM4E (0.41) | KDM4ETYMPTAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116623197-A | Electrochemical synthesis method of target product based on movable gel | 东南大学 | 2023-08-22 | — | — | CN | claimed |
| CN-113150041-B | Preparation method of thiooligonucleotide | 北京悦康科创医药科技股份有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-4709857-A1 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE | Astrazeneca AB (SE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4605403-B1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| EP-4605403-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025103453-A1 | SIRNA FOR INHIBITING ANGIOTENSINOGEN EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025103457-A1 | SIRNA FOR INHIBITING LPA EXPRESSION AND USE THEREOF | 纳肽得(青岛)生物医药有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-120020252-A | SiRNA for inhibiting LPA expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-120005877-A | SiRNA for inhibiting expression of complement factor B and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-120005876-A | SiRNA for inhibiting expression of angiotensinogen and application thereof | 纳肽得(青岛)生物医药有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2024231559-A1 | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | WO | disclosed |
| US-8846885-B2 | Oligonucleotide with protected base | AJINOMOTO CO., INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | AJINOMOTO CO., INC. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20030203356-A1 | RNase L activator-antisense complexes | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1175432-A4 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHOSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS INC (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1175432-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6214805-B1 | GENES, GENE SIGNALS, GENOMES RNA STRANDS AND RESPIRATORY SYNCYTIAL VIRUS WITH PROMOTERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-04-10 | — | — | US | disclosed |
| WO-2000068241-A1 | PROCESSES FOR THE SYNTHESIS OF OLIGOMERS USING PHUSPHORAMIDITE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-1007655-A1 | RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (US) | 2000-06-14 | — | — | EP | disclosed |
| US-5998602-A | RNase L activators and antisense oligonucleotides effective to treat RSV infections | THE CLEVELAND CLINIC FOUINDATION AND GOVERNMENT (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267697-A1 | OLIGONUCLEOTIDE WITH PROTECTED BASE | POLRMT, POLN, RNGTT | KDM4E 3631/4885TYMP 26/4885TAS1R3 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.